Neurosterix is a biopharmaceutical company focused on developing allosteric modulators for the treatment of neurological disorders. Our drug discovery and development platform identifies and develops allosteric modulators.
Products, services, technology
- M4 PAM – Schizophrenia and other psychosis – Started IND enabling studies in Q3 2024
- mGlu7 NAM – Mood disorders – Start IND enabling studies in H1 2025
- mGlu2 NAM – Cognition – Enter clinical candidate selection in H1 2025
- Undisclosed – CNS – Start lead optimization in H1 2025
- https://www.neurosterix.com/
- +41 22 884 15 55
- Send an email
- Tim Dyer